AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration

Development candidate ATX0926 enters IND-enabling stage of development expanding AstronauTx’s pipeline of therapies targeting sleep biology Represents the successful outcome of a multi-year scientific collaboration between AstronauTx and Saniona Saniona receives shares in AstronauTx with a value of US$5 million London, UK and Copenhagen, Denmark, 10 August 2026 – Saniona (OMX: SANION), a clinical-stage biopharmaceutical […]

Read more

AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer

AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development Strategy.

Read more

AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board

Seasoned executive with extensive board experience across US and European biotechnology companies Brings extensive operational, strategic and transactional expertise as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture to treat neurodegenerative diseases London, UK, 7 January 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological […]

Read more

AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team

London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member of the Board, and Magnus Ivarsson as Chief Translation and Early Development Officer.

Read more

AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease

London UK, 9 October 2023 – AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announced the completion of a £48 million ($61 million) Series A financing.

Read more

Saniona enters into collaboration agreement with AstronauTx in Alzheimer’s disease

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels, today announced a new research collaboration with AstronauTx in Alzheimer’s disease. Saniona may receive up to SEK 1.9 billion ($177 million) in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.

Read more